Moderna stock joins Nasdaq-100 as Citi raises target to USD 80
π Moderna joins the Nasdaq-100 index on October 9, 2026, replacing Warner Bros. Discovery and triggering expected passive buying from index-tracking funds.
π Citigroup downgraded Moderna to a Sell rating on September 30, 2026, while raising its price target to USD 80 from USD 60.
π° The stock closed at USD 190.01 on October 2, 2026, trading 57.9% above Citi's new price target and near its 52-week high of USD 208.90.
π Q2 2026 revenue reached USD 145 million, a 2% increase year-over-year, while the company reported a GAAP net loss of USD 782 million.
π¬ Investors await clinical data for autogene, Moderna's personalized cancer vaccine in development with Merck, to be presented on October 24, 2026.
Bullish Signals
- Moderna was added to the Nasdaq-100 index effective October 9, 2026, which will likely trigger substantial passive capital inflows from funds tracking the benchmark.
- The company reported Q2 2026 revenue of USD 145 million, marking a 2% year-over-year growth despite ongoing operational losses.
Risk Factors
- Citigroup downgraded Moderna to a Sell rating on September 30, 2026, citing that the current market valuation is disconnected from fundamental value.
- The stock trades at USD 190.01, which is 57.9% above Citi's new price target of USD 80, indicating a significant bearish divergence between market price and analyst consensus.
- Moderna reported an adjusted loss per share of USD 1.97 and a GAAP net loss of USD 782 million for the second quarter of 2026.
Full Analysis
Moderna Inc. (MRNA) was added to the Nasdaq-100 index effective October 9, 2026, replacing Warner Bros. Discovery. This inclusion is expected to drive significant passive capital inflows into the stock as funds tracking the benchmark adjust their portfolios. The move marks a structural shift in the company's market classification, elevating its profile among large-cap non-financial technology and healthcare leaders.
Despite the index inclusion, analyst sentiment remains mixed following a downgrade by Citigroup on September 30, 2026. Citi downgraded Moderna from Hold to Sell while simultaneously raising its price target to USD 80 from USD 60. This divergence highlights a disconnect between the market's current valuation of approximately USD 190 per share and the analyst's fundamental outlook, which suggests the stock is overvalued relative to its projected performance.
Financially, Moderna reported Q2 2026 revenue of USD 145 million, representing a modest 2% year-over-year increase. The company posted an adjusted loss per share of USD 1.97 and a GAAP net loss of USD 782 million for the quarter. Investors are closely watching upcoming clinical data for autogene, its personalized cancer vaccine developed with Merck, which is scheduled to be presented at the European Society for Medical Oncology Congress on October 24, 2026.